Grants and Contributions:
Title:
Investigating the synergies of targeted radiotherapy and immunotherapy for treating cancer
Agreement Number:
914681
Agreement Value:
$75,000.00
Agreement Date:
Oct 1, 2018 - Sep 30, 2019
Description:
Fusion Pharmaceuticals, Inc. is a new Canadian pharmaceutical company that develops innovative targeted radiotherapy drugs. The project is focused on studying the synergistic effects of Fusion’s targeted radiotherapies with immunotherapies to create new cancer treatment strategies and expand investment and commercialization opportunities for Fusion.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Hamilton, Ontario, CA L8P 0A6
Reference Number:
172-2018-2019-Q4-914681
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
823021795
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 75,000 dollars.
Amendment Date
Mar 5, 2019
Recipient's Legal Name:
Fusion Pharmaceuticals Inc.
Federal Riding Name:
Hamilton Centre
Federal Riding Number:
35035
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: